β-Glucocerebrosidase activity in GBA -linked Parkinson disease
- 15 June 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 95 (6), e685-e696
- https://doi.org/10.1212/wnl.0000000000009989
Abstract
Objective To test the relationship between clinically relevant types of GBA mutations (none, risk variants, mild mutations, severe mutations) and β-glucocerebrosidase activity in patients with Parkinson disease (PD) in cross-sectional and longitudinal case-control studies. Methods A total of 481 participants from the Harvard Biomarkers Study (HBS) and the NIH Parkinson's Disease Biomarkers Program (PDBP) were analyzed, including 47 patients with PD carrying GBA variants (GBA-PD), 247 without a GBA variant (idiopathic PD), and 187 healthy controls. Longitudinal analysis comprised 195 participants with 548 longitudinal measurements over a median follow-up period of 2.0 years (interquartile range, 1–2 years). Results β-Glucocerebrosidase activity was low in blood of patients with GBA-PD compared to healthy controls and patients with idiopathic PD, respectively, in HBS (p < 0.001) and PDBP (p < 0.05) in multivariate analyses adjusting for age, sex, blood storage time, and batch. Enzyme activity in patients with idiopathic PD was unchanged. Innovative enzymatic quantitative trait locus (xQTL) analysis revealed a negative linear association between residual β-glucocerebrosidase activity and mutation type with p < 0.0001. For each increment in the severity of mutation type, a reduction of mean β-glucocerebrosidase activity by 0.85 μmol/L/h (95% confidence interval, −1.17, −0.54) was predicted. In a first longitudinal analysis, increasing mutation severity types were prospectively associated with steeper declines in β-glucocerebrosidase activity during a median 2 years of follow-up (p = 0.02). Conclusions Residual activity of the β-glucocerebrosidase enzyme measured in blood inversely correlates with clinical severity types of GBA mutations in PD. β-Glucocerebrosidase activity is a quantitative endophenotype that can be monitored noninvasively and targeted therapeutically.This publication has 39 references indexed in Scilit:
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsAnnals of Neurology, 2012
- Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2Annals of Neurology, 2011
- Association of SNCA with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker StudyMovement Disorders, 2011
- α-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher DiseasesOnline Journal of Public Health Informatics, 2011
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in SynucleinopathiesCell, 2011
- CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathyProceedings of the National Academy of Sciences of the United States of America, 2011
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's DiseaseThe New England Journal of Medicine, 2009
- GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synucleinProceedings of the National Academy of Sciences of the United States of America, 2008
- The Need for Appropriate Genotyping Strategies for Glucocerebrosidase Mutations in Cohorts With Parkinson DiseaseArchives of Neurology, 2008
- Molecular markers of early Parkinson's disease based on gene expression in bloodProceedings of the National Academy of Sciences of the United States of America, 2007